Hydrocortisone with benzalkonium, dimeticone & nystatin
Brand names: Timodine
A topical combination of hydrocortisone (a mild corticosteroid), nystatin (an antifungal), benzalkonium chloride (an antiseptic) and dimeticone (a water-repellent barrier), used for inflamed skin conditions such as napkin and intertriginous dermatitis where candidal infection is present or suspected.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Hydrocortisone reduces local inflammation, nystatin binds fungal membrane sterols to treat Candida, benzalkonium provides antibacterial/antiseptic action and dimeticone forms a protective water-repellent barrier over the skin.
Prescribing in practice
- Apply thinly to the affected area for short courses only, as occlusion in skin folds or under nappies enhances steroid absorption and the risk of skin thinning, especially in infants.
- It is intended for inflamed candidal or intertriginous eruptions, not for untreated bacterial or viral skin infection where the steroid component could worsen the picture.
- Avoid the face and prolonged use unless specifically directed.
Monitoring
Review the skin response over the short treatment course and reassess if there is no improvement or signs of spreading or unresolved infection.
Counselling the patient
- Apply a thin layer to the affected skin only, for as long as advised and no longer.
- Use a separate barrier or emollient routine for nappy care as directed, and change nappies frequently.
- Seek review if the rash worsens, weeps or fails to settle.
Evidence & guidelines
Combined topical mild corticosteroid, antifungal and barrier preparations are established for short-term treatment of inflamed candidal napkin and flexural dermatitis per the SPC.
Reference: Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Steroid Dose Equivalence · Medications
- Adrenal Insufficiency Assessment · Adrenal
- Adrenal Crisis Risk Score · Adrenal Disorders
- Lille Model (Steroid Response in Alcoholic Hepatitis) · Alcoholic Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Steroid Conversion Calculator · Drug Dosing
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD